Advagene Biopharma Co (ROCO:6709) Long-Term Capital Lease Obligation : NT$0.00 Mil (As of Jun. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Advagene Biopharma Co Long-Term Capital Lease Obligation?

Advagene Biopharma Co's Long-Term Capital Lease Obligation for the quarter that ended in Jun. 2023 was NT$0.00 Mil.

Advagene Biopharma Co's quarterly Long-Term Capital Lease Obligation declined from Jun. 2022 (NT$1.63 Mil) to Dec. 2022 (NT$0.65 Mil) and declined from Dec. 2022 (NT$0.65 Mil) to Jun. 2023 (NT$0.00 Mil).

Advagene Biopharma Co's annual Long-Term Capital Lease Obligation declined from Dec. 2021 (NT$2.57 Mil) to Dec. 2022 (NT$0.65 Mil) and declined from Dec. 2022 (NT$0.65 Mil) to Dec. 2023 (NT$0.00 Mil).

Advagene Biopharma Co Long-Term Capital Lease Obligation Historical Data

The historical data trend for Advagene Biopharma Co's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Advagene Biopharma Co Long-Term Capital Lease Obligation Chart

Advagene Biopharma Co Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

4.40

2.57

0.65

Advagene Biopharma Co Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial										2.57	1.63	0.65	-	-

Advagene Biopharma Co (ROCO:6709) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Advagene Biopharma Co Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Advagene Biopharma Co's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Advagene Biopharma Co (ROCO:6709) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Advagene Biopharma Co Ltd (ROCO:6709) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

Sector 1, Neihu Road, 6 Floor, No.308, Neihu District, Taipei, TWN, 114

Website

http://www.advagene.com.tw

Advagene Biopharma Co Ltd is a Taiwan based immune-modulatory platform-based drug developer. The company has completed technology transfer with DCB for detoxified LT Adjuvant Technology Platform. Its product development includes nasal spray influenza vaccine (LT-Flu), allergy vaccines (LT-Allergy), and other vaccines.

Advagene Biopharma Co (ROCO:6709) Headlines

No Headlines